Clinical and Molecular Hepatology (Clin Mol Hepatol, CMH)

Correspondence

Correspondence to letter to the editor on “Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: Insights from the IMbrave150 trial”

Sung Hwan Lee, Sun Young Yim, Ji Hoon Kim, Sunyoung S Lee, Ahmed O Kaseb, Peng Wei, Ju-Seog Lee

Clin Mol Hepatol. 2025;31(1):e110-e112. Published online October 2, 2024

DOI: https://doi.org/10.3350/cmh.2024.0828

View: 866 Download: 47

Correspondence to editorial 2 on “Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: insights from the IMbrave150 trial”

Sun Young Yim, Sung Hwan Lee, Ji Hoon Kim, Sunyoung S Lee, Ahmed O Kaseb, Ju-Seog Lee

Clin Mol Hepatol. 2025;31(1):e84-e86. Published online October 7, 2024

DOI: https://doi.org/10.3350/cmh.2024.0830

View: 781 Download: 31

Correspondence to editorial 1 on “Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: insights from the IMbrave150 Trial”

Sung Hwan Lee, Sun Young Yim, Ji Hoon Kim, Sunyoung S. Lee, Ahmed O. Kaseb, Ju-Seog Lee

Clin Mol Hepatol. 2025;31(1):e81-e83. Published online October 7, 2024

DOI: https://doi.org/10.3350/cmh.2024.0829

View: 830 Download: 33 Crossref: 1

Original Article

Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: Insights from the IMbrave150 trial

Sun Young Yim, Sung Hwan Lee, Seung-Woo Baek, Bohwa Sohn, Yun Seong Jeong, Sang-Hee Kang, Kena Park, Hyewon Park, Sunyoung S. Lee, Ahmed O. Kaseb, Young Nyun Park, Sun-Hee Leem, Michael A. Curran, Ji Hoon Kim, Ju-Seog Lee

Clin Mol Hepatol. 2024;30(4):807-823. Published online July 23, 2024

DOI: https://doi.org/10.3350/cmh.2024.0333

View: 3138 Download: 315 Web of Science: 8 Crossref: 2

Impacts of muscle mass dynamics on prognosis of outpatients with cirrhosis

Tae Hyung Kim, Young Kul Jung, Hyung Joon Yim, Joo Won Baik, Sun Young Yim, Young-Sun Lee, Yeon Seok Seo, Ji Hoon Kim, Jong Eun Yeon, Kwan Soo Byun

Clin Mol Hepatol. 2022;28(4):876-889. Published online September 19, 2022

DOI: https://doi.org/10.3350/cmh.2022.0231

View: 5306 Download: 140 Web of Science: 17 Crossref: 16

Case Report

Mycophenolate mofetil as an alternative treatment for autoimmune hepatitis

Seung Woon Park, Soon Ho Um, Han Ah Lee, Sang Hyun Kim, Yura Sim, Sun Young Yim, Yeon Seok Seo, Ho Sang Ryu

Clin Mol Hepatol. 2016;22(2):281-285. Published online June 1, 2016

DOI: https://doi.org/10.3350/cmh.2015.0040

View: 12421 Download: 183 Web of Science: 9 Crossref: 11

Gastrectomy for the treatment of refractory gastric ulceration after radioembolization with ⁹⁰Y microspheres

Sun Young Yim, Jin Dong Kim, Jin Yong Jung, Chang Ha Kim, Yeon Seok Seo, Hyung Joon Yim, Soon Ho Um, Ho Sang Ryu, Yun Hwan Kim, Chong Suk Kim, Eun Shin

Clin Mol Hepatol. 2014;20(3):300-305. Published online September 25, 2014

DOI: https://doi.org/10.3350/cmh.2014.20.3.300

View: 8882 Download: 66 Web of Science: 9 Crossref: 11

Spinal cord injury after conducting transcatheter arterial chemoembolization for costal metastasis of hepatocellular carcinoma

Sang Jung Park, Chang Ha Kim, Jin Dong Kim, Soon Ho Um, Sun Young Yim, Min Ho Seo, Dae In Lee, Jun Hyuk Kang, Bora Keum, Yong Sik Kim

Clin Mol Hepatol. 2012;18(3):316-320. Published online September 25, 2012

DOI: https://doi.org/10.3350/cmh.2012.18.3.316

View: 8971 Download: 91 Crossref: 7

Original Article

Optimal time for repeating the IgM anti-hepatitis A virus antibody test in acute hepatitis A patients with a negative initial test

Jong Jin Hyun, Yeon Seok Seo, Hyonggin An, Sun Young Yim, Min Ho Seo, Hye Sook Kim, Chang Ha Kim, Ji Hoon Kim, Bora Keum, Yong Sik Kim, Hyung Joon Yim, Hong Sik Lee, Soon Ho Um, Chang Duck Kim, Ho Sang Ryu

Clin Mol Hepatol. 2012;18(1):56-62. Published online March 22, 2012

DOI: https://doi.org/10.3350/kjhep.2012.18.1.56

View: 7529 Download: 58 Crossref: 9

Erratum

Erratum to ‘Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: Insights from the IMbrave150 trial’ [Clin Mol Hepatol 2024;30:807-823]

DOI: https://doi.org/10.3350/cmh.2024.0333e [Epub ahead of print]

View: 355 Download: 28

1 |

Viewed By 7187	MAFLD: How is it different from NAFLD?
Viewed By 6634	Epidemiology of metabolic dysfunction-associated steatotic liver disease
Viewed By 5468	Global incidence and prevalence of nonalcoholic fatty liver disease
Viewed By 5257	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Viewed By 4734	Role of noninvasive tests in the prognostication of metabolic dysfunction-associated steatotic liver disease

Cited By 298	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Cited By 269	Global incidence and prevalence of nonalcoholic fatty liver disease
Cited By 181	MAFLD: How is it different from NAFLD?
Cited By 93	Non-alcoholic fatty liver disease: Definition and subtypes
Cited By 88	Pathogenesis and treatment of non-alcoholic steatohepatitis and its fibrosis

Search